Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NRBO
- Price
- 1.89
- Stock movement down
- -0.09 (-4.55%)
- Company name
- Neurobo Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 16.28M
- Ent value
- 3.81M
- Price/Sales
- 4071.06
- Price/Book
- 1.26
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -81.13%
- 1 year return
- -38.44%
- 3 year return
- -81.12%
- 5 year return
- -75.09%
- 10 year return
- -
Last updated: 2025-04-18
DIVIDENDS
NRBO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4071.06 |
| Price to Book | 1.26 |
| EV to Sales | 952.06 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 8.62M |
| EPS (TTM) | -2.72 |
| FCF per share (TTM) | -2.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.00K |
| Gross profit (TTM) | -10.00K |
| Operating income (TTM) | -28.89M |
| Net income (TTM) | -27.73M |
| EPS (TTM) | -2.72 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -250.00% |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 21.67M |
| Net receivables | 0.00 |
| Total current assets | 21.93M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 239.00K |
| Total assets | 22.15M |
| Accounts payable | 1.02M |
| Short/Current long term debt | 154.00K |
| Total current liabilities | 9.11M |
| Total liabilities | 9.19M |
| Shareholder's equity | 12.95M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -22.68M |
| Capital expenditures (TTM) | 17.00K |
| Free cash flow (TTM) | -22.69M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -214.10% |
| Return on Assets | -125.23% |
| Return on Invested Capital | -212.87% |
| Cash Return on Invested Capital | -174.18% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.00 |
| Daily high | 2.00 |
| Daily low | 1.75 |
| Daily Volume | 23K |
| All-time high | 126420.00 |
| 1y analyst estimate | 26.67 |
| Beta | -0.28 |
| EPS (TTM) | -2.72 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| NRBO | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.30% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 24 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -85.06% | -11.07% |
| Avg time to new high | 102 days | 12 days |
| Max time to new high | 1886 days | 1805 days |
COMPANY DETAILS
Marketcap
16.28M
Marketcap category
Small-cap
Description
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Employees
8
Website
Investor relations
-
SEC filings
CEO
Jeong Gu Kang
Country
USA
City
Boston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner